Findings seen in patients with microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancer. (HealthDay News) — For patients with microsatellite-instability-high (MSI-H) ...

CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with chemotherapy alone for patients with resectable non-small cell lung cancer (NSCLC ...

Tina Cascone, MD, PhD, of the University of Texas MD Anderson Cancer Center, discusses the impact of the CheckMate 77T study on the treatment approach for non–small cell lung cancer (NSCLC). Tina ...

Please provide your email address to receive an email when new articles are posted on . In this video, Stephen M. Ansell, MD, PhD, discussed updated study results showing an advantage of ...

Adding nivolumab (Opdivo) to neoadjuvant chemotherapy followed by adjuvant treatment with the PD-1 inhibitor alone significantly increased event-free survival (EFS) for patients with resectable ...

Significantly more patients had 18-month event-free survival in nivolumab vs chemotherapy group. HealthDay News — For patients with resectable non-small cell lung cancer (NSCLC), perioperative ...

The FDA approval of nivolumab plus cisplatin and gemcitabine marks the first concurrent immunotherapy-chemotherapy combination for the population. The trial showed the combination significantly ...

Randomized Controlled Trial of Virtually Delivered Cognitive Behavioral Therapy for Insomnia to Address Perceived Cancer-Related Cognitive Impairment in Cancer Survivors Patients with unresectable, ...

(San Diego, Calif--September 8, 2024, 10:05 a.m. PCT) – New data from landmark analysis presented today report a decreased risk of disease recurrence or death in patients with resectable NSCLC who ...

Trial participants were randomly assigned to receive neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo every 3 weeks. HealthDay News — For patients with resectable ...